28 November 2024
N4 Pharma plc
("N4 Pharma" or the "Company")
Grant of Options
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, announces that, on 27 November 2024, the Board granted 15 million options (the "Options") over ordinary shares of 0.4p each in the Company to certain directors of N4 Pharma as follows:
| Director |
| Number of options granted |
| | | |
| Nigel Theobold (Chief Executive Officer) | | 6,000,000 |
| Michael Palfreyman (Non-Executive Director) | | 3,000,000 |
| Dr Chris Britten (Non-Executive Chairman) | | 3,000,000 |
| Luke Cairns (Executive Director) | | 3,000,000 |
The Options have an exercise price of 0.75p and vest in three equal tranches on the first, second and third anniversaries from the date of grant. The Options have a term of ten years from the date of grant.
The FCA notifications, made in accordance with the requirements of the Market Abuse Regulation, are appended below.
For more information please contact:
| N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director
Engage with us directly at N4 Pharma Investor Hub
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
|
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44(0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope | Tel: +44(0)20 3657 0050 |
| | |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.
N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Nigel Theobold
| ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b)
| Initial notification /Amendment | Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | N4 Pharma plc | ||||
| b) | LEI | 213800I841D2RKMFK955 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares of 0.4p each
Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32
| ||||
| b) | Nature of the transaction | Issue of options over ordinary shares of 0.4p each
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
n/a | ||||
| e) | Date of the transaction | 27 November 2024 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Michael Palfreyman
| ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b)
| Initial notification /Amendment | Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | N4 Pharma plc | ||||
| b) | LEI | 213800I841D2RKMFK955 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares of 0.4p each
Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32
| ||||
| b) | Nature of the transaction | Issue of options over ordinary shares of 0.4p each
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
n/a | ||||
| e) | Date of the transaction | 27 November 2024 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Dr Chris Britten
| ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Chairman | ||||
| b)
| Initial notification /Amendment | Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | N4 Pharma plc | ||||
| b) | LEI | 213800I841D2RKMFK955 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares of 0.4p each
Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32
| ||||
| b) | Nature of the transaction | Issue of options over ordinary shares of 0.4p each
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
n/a | ||||
| e) | Date of the transaction | 27 November 2024 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Luke Cairns
| ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Director | ||||
| b)
| Initial notification /Amendment | Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | N4 Pharma plc | ||||
| b) | LEI | 213800I841D2RKMFK955 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument
Identification code | Options over Ordinary Shares of 0.4p each
Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32
| ||||
| b) | Nature of the transaction | Issue of options over ordinary shares of 0.4p each
| ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
n/a | ||||
| e) | Date of the transaction | 27 November 2024 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
